FAP and colorectal carcinoma: The serum concentration–time data of [131I]I-F19 mAb from study participants was obtained after co-infusion of the F19 mAb and radiopharmaceutical with colorectal carcinoma subjects administered a 0.2 mg dose (n = 4) or a 2 mg dose (n = 3) of the F19 mAb, while all subjects with soft tissue sarcoma were administered a 1 mg dose of the anti-FAP antibody.